A double blind randomized placebo controlled phase I/II study assessing the safety and efficacy of allogeneic bone marrow derived mesenchymal stem cell in critical limb ischemia

被引:165
作者
Gupta, Pawan K. [1 ]
Chullikana, Anoop [1 ]
Parakh, Rajiv [2 ]
Desai, Sanjay [3 ]
Das, Anjan [1 ]
Gottipamula, Sanjay [1 ]
Krishnamurthy, Sagar [1 ]
Anthony, Naveen [1 ]
Pherwani, Arun [4 ]
Majumdar, Anish S. [1 ]
机构
[1] Stempeut Res Pvt Ltd, Bangalore 560066, Karnataka, India
[2] Medanta Medic, Sect 38, Dept Vasc Surg, Gurgaon 122001, Haryana, India
[3] MS Ramaiah Mem Hosp, Dept Vasc & Endovasc Surg, Bangalore 560054, Karnataka, India
[4] Univ Hosp North Staffordshire, Newcastle Upon Tyne ST50QP, Tyne & Wear, England
关键词
CLI; Mesenchymal stem cells; ABPI; Bone marrow; Allogeneic; THERAPEUTIC ANGIOGENESIS; MONONUCLEAR-CELLS; STROMAL CELLS; AUTOLOGOUS TRANSPLANTATION; IMPLANTATION; PROLIFERATION; SURVIVAL; DISEASE;
D O I
10.1186/1479-5876-11-143
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: Peripheral vascular disease of the lower extremities comprises a clinical spectrum that extends from no symptoms to presentation with critical limb ischemia (CLI). Bone marrow derived Mesenchymal Stem Cells (BM-MSCs) may ameliorate the consequences of CLI due to their combinatorial potential for inducing angiogenesis and immunomodulatory environment in situ. The primary objective was to determine the safety of BM-MSCs in patients with CLI. Methods: Prospective, double blind randomized placebo controlled multi-center study was conducted in patients with established CLI as per Rutherford classification in category II-4, III-5, or III-6 with infra-inguinal arterial occlusive disease and were not suitable for or had failed revascularization treatment. The primary end point was incidence of treatment - related adverse events (AE). Exploratory efficacy end points were improvement in rest pain, increase in Ankle Brachial Pressure Index (ABPI), ankle pressure, healing of ulcers, and amputation rates. Twenty patients (BM-MSC: Placebo = 1:1) were administered with allogeneic BM-MSCs at a dose of 2 million cells/kg or placebo (PlasmaLyte A) at the gastrocnemius muscle of the ischemic limb. Results: Improvement was observed in the rest pain scores in both the arms. Significant increase in ABPI and ankle pressure was seen in BM-MSC arm compared to the placebo group. Incidence of AEs in the BM-MSC arm was 13 vs. 45 in the placebo arm where as serious adverse events (SAE) were similar in both the arms (5 in BM-MSC and 4 in the placebo group). SAEs resulted in death, infected gangrene, amputations in these patients. It was observed that the SAEs were related to disease progression and not related to stem cells. Conclusion: BM-MSCs are safe when injected IM at a dose of 2 million cells/kg body weight. Few efficacy parameters such as ABPI and ankle pressure showed positive trend warranting further studies.
引用
收藏
页数:11
相关论文
共 39 条
[11]   Autologous bone-marrow mononuclear cell implantation for patients with Rutherford grade II-III thromboangiitis obliterans [J].
Durdu, Serkan ;
Akar, Ahmet Ruchan ;
Arat, Mutlu ;
Sancak, Tanzer ;
Eren, Neyyir Tuncay ;
Ozyurda, Umit .
JOURNAL OF VASCULAR SURGERY, 2006, 44 (04) :732-739
[12]  
Esato K, 2002, CELL TRANSPLANT, V11, P747
[13]   A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of Intravenous Adult Human Mesenchymal Stem Cells (Prochymal) After Acute Myocardial Infarction [J].
Hare, Joshua M. ;
Traverse, Jay H. ;
Henry, Timothy D. ;
Dib, Nabil ;
Strumpf, Robert K. ;
Schulman, Steven P. ;
Gerstenblith, Gary ;
DeMaria, Anthony N. ;
Denktas, Ali E. ;
Gammon, Roger S. ;
Hermiller, James B., Jr. ;
Reisman, Mark A. ;
Schaer, Gary L. ;
Sherman, Warren .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 54 (24) :2277-2286
[14]   ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (Lower extremity, renal, mesenteric, and abdominal aortic): Executive summary [J].
Hirsch, AT ;
Haskal, ZJ ;
Hertzer, NR ;
Bakal, CW ;
Creager, MA ;
Halperin, JL ;
Hiratzka, LF ;
Murphy, WRC ;
Olin, JW ;
Puschett, JB ;
Rosenfield, KA ;
Sacks, D ;
Stanley, JC ;
Taylor, LM ;
White, CJ ;
White, J ;
White, RA ;
Antman, EM ;
Smith, SC ;
Adams, CD ;
Anderson, JL ;
Faxon, DP ;
Fuster, V ;
Gibbons, RJ ;
Halperin, JL ;
Hiratzka, LF ;
Hunt, SA ;
Jacobs, AK ;
Nishimura, R ;
Ornato, JP ;
Page, RL ;
Riegel, B .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (06) :1239-1312
[15]   Autologous Bone-Marrow Mononuclear Cell Implantation Reduces Long-Term Major Amputation Risk in Patients With Critical Limb Ischemia A Comparison of Atherosclerotic Peripheral Arterial Disease and Buerger Disease [J].
Idei, Naomi ;
Soga, Junko ;
Hata, Takaki ;
Fujii, Yuichi ;
Fujimura, Noritaka ;
Mikami, Shinsuke ;
Maruhashi, Tatsuya ;
Nishioka, Kenji ;
Hidaka, Takayuki ;
Kihara, Yasuki ;
Chowdhury, Moniruddin ;
Noma, Kensuke ;
Taguchi, Akira ;
Chayama, Kazuaki ;
Sueda, Taijiro ;
Higashi, Yukihito .
CIRCULATION-CARDIOVASCULAR INTERVENTIONS, 2011, 4 (01) :15-25
[16]   Safety and efficacy of autologous progenitor cell transplantation for therapeutic angiogenesis in patients with critical limb ischemia [J].
Kajiguchi, Masahiro ;
Kondo, Takahisa ;
Izawa, Hideo ;
Kobayashi, Masayoshi ;
Yamamoto, Koji ;
Shintani, Satoshi ;
Numaguchi, Yasushi ;
Naoe, Tomoki ;
Takamatsu, Junki ;
Komori, Kimihiro ;
Murohara, Toyoaki .
CIRCULATION JOURNAL, 2007, 71 (02) :196-201
[17]   Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization [J].
Kalka, C ;
Masuda, H ;
Takahashi, T ;
Kalka-Moll, WM ;
Silver, M ;
Kearney, M ;
Li, T ;
Isner, JM ;
Asahara, T .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (07) :3422-3427
[18]   Intramuscular Transplantation of G-CSF-Mobilized CD34+ Cells in Patients With Critical Limb Ischemia: A Phase I/IIa, Multicenter, Single-Blinded, Dose-Escalation Clinical Trial [J].
Kawamoto, Atsuhiko ;
Katayama, Minako ;
Handa, Nobuhiro ;
Kinoshita, Makoto ;
Takano, Haruna ;
Horii, Miki ;
Sadamoto, Kazuyo ;
Yokoyama, Ayumi ;
Yamanaka, Takeharu ;
Onodera, Rie ;
Kuroda, Akiko ;
Baba, Rie ;
Kaneko, Yuichiro ;
Tsukie, Tomio ;
Kurimoto, Yasuo ;
Okada, Yukikatsu ;
Kihara, Yasuki ;
Morioka, Shigefumi ;
Fukushima, Masanori ;
Asahara, Takayuki .
STEM CELLS, 2009, 27 (11) :2857-2864
[19]   Stem cell and progenitor cell therapy in peripheral artery disease A critical appraisal [J].
Lawall, Holger ;
Bramlage, Peter ;
Amann, Berthold .
THROMBOSIS AND HAEMOSTASIS, 2010, 103 (04) :696-709
[20]   Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex [J].
Le Blanc, K ;
Tammik, L ;
Sundberg, B ;
Haynesworth, SE ;
Ringdén, O .
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2003, 57 (01) :11-20